Table of frequent aberrant markers in AML: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
---- | ---- | ||
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. | The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a change in diagnosis.</br>The most frequent "abberencies" observed in AML are</br> | ||
</br>(1) The expression of CD7 by nearly half of cases</br>(2) The expression of CD19 (often associated with particular AML subtypes) | |||
The most frequent "abberencies" observed in AML are | |||
</br>(1) The expression of CD7 by nearly half of cases | |||
</br>(2) The expression of CD19 | |||
----- | ----- | ||
Revision as of 17:23, 12 January 2024
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a change in diagnosis.
The most frequent "abberencies" observed in AML are
(1) The expression of CD7 by nearly half of cases
(2) The expression of CD19 (often associated with particular AML subtypes)
CD19 BCRABL TdT 7%
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage CD2 CD4, 36 38 MONOCYTIC 5%
BASOPHILIC 123, 203, 11B 22
Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: CD19 30% CBF RUNX1, BCRABL CD56 CBF RUNX1 NPM1 OFTEN LACK CD34